- Fraudulent Email Warning（27KB）
News Release
- August 13, 2026
- Impact on the NIPRO Group from the Earthquake in Colombia (326KB)
- August 4, 2026
- NIPRO Introduces Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance (318KB)
Announcement of Spryte Medical, a US Affiliate of NIPRO, Completion of Subject Enrollment in the “INSYTE” US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment (270KB) - July 30, 2026
- NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States (195KB)
IR News
- August 10, 2026
- Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP] / IR Materials
- June 26, 2026
- Notice of Resolutions at the 73rd Annual General Meeting of Shareholders / The 73rd Shareholders’ Newsletter
- June 3, 2026
- Notice of the 73rd Annual General Meeting of Shareholders
Our Business
Meeting the needs of front line medical treatment with unique products and technologies
To meet the needs of the front line of medical treatment, NIPRO creates unique products at its four research and development sites while leveraging the technologies cultivated in its various businesses.
Mission, Vision, Value
We will work as a truly global comprehensive medical manufacturer with a willingness to consider patient and user viewpoints.
